Publications by authors named "L F Colomo"
Article Synopsis
- Aggressive large B-cell lymphomas (LBCL) have diverse biological traits; detecting MYC rearrangements (MYCr) is crucial for understanding their prognosis.
- Current recommendations urge performing cytogenetic tests on all aggressive LBCL cases to identify MYCr, but due to its low occurrence, affordable screening options are necessary.
- Researchers developed a scoring system and algorithm based on immunohistochemical profiles of CD10, LMO2, and MYC to effectively screen for MYCr, achieving high sensitivity and predictive values in both training and validation series.
Article Synopsis
- B-cell epidermotropism is a rare occurrence in skin lymphomas, typically seen in systemic lymphomas like splenic marginal zone lymphoma.
- This type of lymphoma can present with skin symptoms before other signs, such as an enlarged spleen, and may involve bone marrow or blood.
- The case discussed highlights the importance for clinicians to recognize this feature, as it may indicate further disease spread and necessitate more thorough initial staging.
Background: is a relevant gene involved in B-cell ontogeny and a survival predictor of aggressive large B-cell lymphomas (aLBCL). Most studies assessing mRNA expression have relied on microarray platforms or qRT-PCR methods, overlooking tissue morphology. In this study, we evaluate RNA expression by chromogenic in situ hybridization (CISH) in normal tissue and in a series of 82 aLBCL.
View Article and Find Full Text PDFFollicular lymphoma (FL) is the most frequent indolent lymphoma. Some patients (10%-15%) experience histologic transformation (HT) to a more aggressive lymphoma, usually diffuse large B-cell lymphoma (DLBCL). This study aimed to validate and improve a genetic risk model to predict HT at diagnosis.
View Article and Find Full Text PDFBackground: Cell-free DNA (cfDNA) analysis has become a promising tool for the diagnosis, prognosis, and monitoring of lymphoma cases. Until now, research in this area has mainly focused on aggressive lymphomas, with scanty information from other lymphoma subtypes.
Methods: We selected 256 patients diagnosed with lymphomas, including a large variety of B-cell and T-cell non-Hodgkin and Hodgkin lymphomas, and quantified cfDNA from plasma at the time of diagnosis.